Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials

Published:2019-09 Issue: Volume:141 Page:163-173
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Ruiz-Schutz Viviane C.^ORCID,Gomes Larissa M.,Mariano Rodrigo C.^ORCID,de Almeida Daniel V.P.^ORCID,Pimenta Juliana M.,Dal Molin Graziela Z.^ORCID,Kater Fabio R.,Yamamura Rosely,Correa Neto Nelson F.,Maluf Fernando C.,Schutz Fabio A.

Funder

BP – A Beneficencia Portuguesa de Sao Paulo

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference38 articles.

1. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors;Abrahams;Ann. Oncol.,2016

2. Assessment and management of cancer-related fatigue in adults;Ahlberg;Lancet,2003

3. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer;Bang;J. Clin. Oncol.,2015

4. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial;Bang;Lancet Oncol.,2017

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis;Taiwanese Journal of Obstetrics and Gynecology;2024-09

2. Evaluation of the efficacy of marine natural products against PARP-1/2 proteins in high-grade serous ovarian cancer: insights into MD and SMD simulations;Journal of Biomolecular Structure and Dynamics;2024-06-17

3. Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials;Expert Review of Anticancer Therapy;2024-01-25

4. Anaemia in Hospitalized Cancer Patients: A Retrospective Study of Two Cohorts before and after the Guideline Update;Oncology Research and Treatment;2024

5. Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer;Frontiers in Endocrinology;2023-10-31